

GF/B46/EDP12 ***Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (India)***

Approved on 25 February 2022

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER10; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

Table 1: Secretariat's Recommendation on Funding from C19RM¹

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country / Multicountry	Grant name	Currency	C19RM 2020 carry-over amount ²	Previously approved C19RM 2021 award ³	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
India	IND-H-NACO	USD	0	75,000,000	0	112,919,394	22.6%	133,710,258	0
	IND-C-PLAN	USD	0	0	1,647,284				
	IND-H-IHAA	USD	4,012,132	0	7,954,785				
	IND-H-SAATHII	USD	6,819,469	0	6,269,158				
	IND-M-TCIF	USD	0	0	651,882				
	IND-T-FIND	USD	9,959,263	0	9,957,640				
	IND-T-IUATLD	USD	0	0	3,566,853				
	IND-T-WJCF	USD	0	0	7,871,792				

¹ The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

² Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

³ This includes Secretariat approved Fast-track and Full Funding awards, as well as awards previously approved by the Board.